Calpastatin Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-21395
Key Product Details
Species Reactivity
Validated:
Human
Applications
Immunocytochemistry/ Immunofluorescence
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Product Summary for Calpastatin Antibody
Immunogen
This antibody was developed against Recombinant Protein corresponding to amino acids: DTIPPEYRHLLDDNGQDKPVKPPTKKSEDSKKPADDQDPIDALSGDLDSCPSTTETSQNTAKDKCKKAASSSKAPKNGGKAKDSA
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for Calpastatin Antibody
Immunocytochemistry/Immunofluorescence: Calpastatin Antibody [NBP3-21395] -
Staining of human cell line HaCaT shows localization to cytosol & endoplasmic reticulum.Applications for Calpastatin Antibody
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
0.25-2 ug/ml
Application Notes
ICC/IF Fixation Permeabilization: Use PFA/Triton X-100.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, pH 7.2, 40% glycerol
Preservative
0.02% Sodium Azide
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Calpastatin
Alternate Names
BS-17, Calpain inhibitor, calpastatin, MGC9402, Sperm BS-17 component
Gene Symbol
CAST
Additional Calpastatin Products
Product Documents for Calpastatin Antibody
Product Specific Notices for Calpastatin Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...